The main risk factor for chronic obstructive pulmonary disease (COPD) is active smoking. However, a considerable amount of people with COPD never smoked, and increasing evidence suggests that adult lung disease can have its origins in prenatal and early life. This article reviews some of the factors that can potentially affect lung development and lung function trajectories throughout the lifespan from genetics and prematurity to respiratory tract infections and childhood asthma. Maternal smoking and air pollution exposure were also analyzed among the environmental factors. The adoption of preventive strategies to avoid these risk factors since the prenatal period may be crucial to prevent, delay the onset or modify the progression of COPD lung disease throughout life.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915555 | PMC |
http://dx.doi.org/10.3390/ijerph20032294 | DOI Listing |
FASEB J
January 2025
Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Renal fibrosis is a common pathological process in various chronic kidney diseases. The accumulation of senescent renal tubular epithelial cells (TECs) in renal tissues plays an important role in the development of renal fibrosis. Eliminating senescent TECs has been proven to effectively reduce renal fibrosis.
View Article and Find Full Text PDFClin Physiol Funct Imaging
January 2025
Centre for Physical Activity Research, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Background: Cardiopulmonary exercise testing (CPET) is usually considered the gold standard for assessing maximal oxygen consumption (V̇O), a health and performance marker in patients with chronic obstructive pulmonary disease (COPD). Despite the widespread application of CPET, the absolute and relative test-retest reliability of CPET-derived metrics remains unexamined.
Objective: To examine and compare test-retest reliability of CPET derived metrics in individuals with COPD and healthy matched controls.
COPD
December 2025
Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Background: Despite limited breakthroughs in COPD pharmacotherapy, recent trials have shown promising results for biologics in COPD patients. However, robust evidence synthesis in this area is currently lacking.
Methods: We conducted a systematic review of MEDLINE, EMBASE, and Cochrane CENTRAL from inception to July 17, 2024, to identify randomized trials of biologic medications in patients with COPD.
J Multimorb Comorb
January 2025
Trinity Health of New England, St. Francis Hospital, Hartford, CT, USA.
Background: Since comorbid conditions are frequently present in chronic obstructive pulmonary disease (COPD) and affect outcome, a composite scoring system to quantify comorbidity might be helpful in assessing mortality risk.
Methods: We tested the hypothesis that the Charlson Comorbidity Index (CCI) score at the time of an outpatient medical clinic encounter for COPD predicts all-cause mortality. Cox Proportional Hazards analyses were used in 200 randomly selected patients to relate CCI scores to all-cause mortality out to 5 years.
Cureus
December 2024
Internal Medicine, Mercy Health St. Vincent Medical Center, Toledo, USA.
We present a case of spontaneous hemorrhage in an emphysematous bulla, complicated by anticoagulation. Bullous emphysema is a well-recognized complication of chronic obstructive pulmonary disease (COPD), and a rare manifestation is hemorrhage into preexisting pulmonary bullae. A 69-year-old male patient presented to the emergency department with hemoptysis, shortness of breath, and productive cough.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!